StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $19.98 | $20.40 | +2.13% | 0.4M |
| 05-12 | $20.40 | $19.16 | -6.08% | 0.3M |
| 05-13 | $19.60 | $19.93 | +1.68% | 0.5M |
| 05-14 | $20.10 | $18.90 | -5.97% | 0.5M |
| 05-15 | $18.45 | $18.34 | -0.60% | 0.6M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $10.00M | $10.00M | $10.00M | $10.00M |
Operating Income | $-383.06M | $-145.07M | $-92.49M | $-37.33M |
Net Income | $-377.74M | $-137.29M | $-52.22M | $-33.57M |
EPS (Diluted) | $-8.44 | $-3.27 | $-2.05 | $-0.80 |
Total Assets | $383.64M | $322.02M | $293.08M | $333.77M |
Total Liabilities | $141.50M | $125.59M | $53.46M | $49.45M |
Cash & Equivalents | $110.64M | $115.56M | $44.01M | $196.55M |
Free Cash Flow OCF − CapEx | $-172.35M | $-119.94M | $-78.81M | $-37.07M |
Shares Outstanding | 54.49M | 42.21M | 42.09M | 41.82M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.